PCSK9 inhibition and type 2 diabetes

Overview of attention for article published in The Lancet Diabetes & Endocrinology, September 2017

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Above-average Attention Score compared to outputs of the same age and source (56th percentile)

Mentioned by

news: 2 news outlets

twitter: 1 X user

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 14 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 2 news stories from 2 outlets.

CV Benefit from PCSK9 Drug Unaltered by Diabetes

MedPage Today, 15 Sep 2017

LISBON -- Presence of diabetes had no bearing on cardiovascular risk reduction with the PCSK9 inhibitor evolocumab (Repatha) in…

CV death risk decreases with evolocumab in atherosclerotic disease

Healio.com, 15 Sep 2017

The risks for cardiovascular death, myocardial infarction and stroke are reduced in adults with atherosclerotic disease with or…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.